
Three New Type 2 Diabetes Treatment Options Approved in the U.S. United States Food and Drug Administration approves NESINA (alogliptin), OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) (BPT) – The number of people living with type 2 diabetes continues to grow. In the United States, it is estimated that approximately 23 million…